ARTICLE | Finance
Global ambitions
Why European biotechs should start courting U.S. capital now
May 16, 2016 7:00 AM UTC
European biotechs not only missed out on the extended bull market that allowed U.S. biotechs to fill their coffers, but also on what could have been an arbitrage opportunity for U.S. investors who found domestic valuations too rich.
The reason was not as simple or obvious as distance, logistics or inconvenience. Neither was the culprit an overabundance of me-too, NRDO and repurposing companies - familiar criticisms of European biotech in years past...